Business
Mesoblast shares savaged on poor COVID trial results – Sydney Morning Herald
The stem cell treatment hopeful plunged 41 per cent at the open after revealing its COVID research was unlikely to meet its goals.
The company, will complete the study, which had been aiming to recruit 300 patients, using the 223 patients already enrolled.
Its the second piece of tough news for Mesoblast, which is backed by high profile investors including billionaire Alex Waislitz, to be released this week, after phase 3 trial results of its heart failure drug caused the stock to plunge at the start of the week. The company released data on Tuesday showing its other product, Revascor, showed reduction in mortality of up to…
-
Noosa News24 hours agoBroncos media boss Melissa Mallet to face court over alleged drink-driving crash
-
General16 hours agoAbattoir worker in serious condition after workplace accident in Echuca
-
General21 hours ago‘Sovereign citizens’ sentenced to prison term in Western Australia for defiance of court order
-
General16 hours agoWoman who reported NSW MP Gareth Ward’s alleged sex crimes cross-examined